Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Treeline Biosciences
Biotech
Treeline reaps $200M series A extension, picks first 3 programs
Tight-lipped Treeline's first programs are an internally developed BCL6 degrader and pan-KRAS inhibitor, along with an EZH2 inhibitor from Hengrui.
Darren Incorvaia
Sep 3, 2025 11:15am
A look at biotech's biggest money raisers of 2024
Mar 7, 2025 9:00am
Biotech's top money raisers: 2024
Mar 3, 2025 5:00am
Lilly, Novartis R&D vets forge cancer biotech—Chutes & Ladders
Apr 30, 2021 9:30am
Ex-Lilly R&D lead launches cancer biotech with Novartis alum
Apr 27, 2021 7:20am
